Therapeutic reference range for olanzapine in schizophrenia: systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy
Objective: Aiming at revising the therapeutic reference range for olanzapine, the present study highlights the association between blood olanzapine levels, clinical effects, and dopamine D2-receptor occupancy for oral and long-acting injectable (LAI) formulations. Data Sources: Databases were system...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 19, 2023
|
| In: |
The journal of clinical psychiatry
Year: 2023, Volume: 84, Issue: 5, Pages: ? |
| ISSN: | 1555-2101 |
| DOI: | 10.4088/JCP.22r14626 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4088/JCP.22r14626
|
| Author Notes: | Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin M. Egberts, Stefanie Fekete, Manfred Gerlach, Ursula Havemann-Reinecke, Xenija M. Lense, Thomas G. Riemer, Georgios Schoretsanitis, Manfred Uhr, Gerald Zernig, Gerhard Gründer, Xenia M. Hart |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1902532171 | ||
| 003 | DE-627 | ||
| 005 | 20241205171946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240913s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4088/JCP.22r14626 |2 doi | |
| 035 | |a (DE-627)1902532171 | ||
| 035 | |a (DE-599)KXP1902532171 | ||
| 035 | |a (OCoLC)1475311395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wesner, Katja |d 1984- |e VerfasserIn |0 (DE-588)1325960853 |0 (DE-627)1885694520 |4 aut | |
| 245 | 1 | 0 | |a Therapeutic reference range for olanzapine in schizophrenia |b systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy |c Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin M. Egberts, Stefanie Fekete, Manfred Gerlach, Ursula Havemann-Reinecke, Xenija M. Lense, Thomas G. Riemer, Georgios Schoretsanitis, Manfred Uhr, Gerald Zernig, Gerhard Gründer, Xenia M. Hart |
| 264 | 1 | |c July 19, 2023 | |
| 300 | |a ? | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.09.2024 | ||
| 520 | |a Objective: Aiming at revising the therapeutic reference range for olanzapine, the present study highlights the association between blood olanzapine levels, clinical effects, and dopamine D2-receptor occupancy for oral and long-acting injectable (LAI) formulations. Data Sources: Databases were systematically searched for randomized controlled trials (RCTs) and uncontrolled trials concerning blood olanzapine levels in relation to clinical outcomes or D2-receptor occupancy using MEDLINE (PubMed), Web of Science, PsycINFO, and Cochrane Library (March 2021, updated in December 2021). We excluded articles not written in English or German and non-human data. Search terms included olanzapine, blood level, drug monitoring, PET, and SPECT. Study Selection: The process of study selection followed a previously published protocol and PRISMA guidelines. A total of 2,824 articles were identified through database search and 1 article via reference list check. Thirty-four studies were suitable for qualitative synthesis, and 13 studies were included in the quantitative analysis. Data Extraction: Reviewers performed data extraction and quality assessment of the included studies independently following the review protocol. Results: Evidence for a relationship between blood olanzapine level and efficacy/side effects (constipation) is considered low (Level C). In total, 3 studies of moderate quality consistently showed therapeutic thresholds of around 20 ng/mL for olanzapine 12 hours post-dose. This threshold is in line with findings from positron emission tomography (PET) studies that suggest optimal drug efficacy (65%-80% D2-receptor occupancy) between 17 and 44 ng/mL. Conclusions: We suggest a therapeutic reference range of 20-40 ng/mL for olanzapine oral and LAI formulations. In this range, optimal treatment response is expected in patients with schizophrenia and schizophrenia spectrum disorders. Side effects, especially weight gain, may already occur at therapeutic levels. However, higher plasma concentrations are in general well tolerated and should not necessarily require a dose reduction in case of good response and tolerance. | ||
| 650 | 4 | |a Antipsychotic Agents | |
| 650 | 4 | |a Benzodiazepines | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Olanzapine | |
| 650 | 4 | |a Receptors, Dopamine D2 | |
| 650 | 4 | |a Reference Values | |
| 650 | 4 | |a Schizophrenia | |
| 700 | 1 | |a Hiemke, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bergemann, Niels |e VerfasserIn |0 (DE-588)170531007 |0 (DE-627)060634154 |0 (DE-576)131408437 |4 aut | |
| 700 | 1 | |a Egberts, Karin M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fekete, Stefanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gerlach, Manfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Havemann-Reinecke, Ursula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lense, Xenija M. |d 1997- |e VerfasserIn |0 (DE-588)1278513981 |0 (DE-627)1831439077 |4 aut | |
| 700 | 1 | |a Riemer, Thomas G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoretsanitis, Georgios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhr, Manfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zernig, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gründer, Gerhard |e VerfasserIn |0 (DE-588)1078251037 |0 (DE-627)838195350 |0 (DE-576)449927644 |4 aut | |
| 700 | 1 | |a Hart, Xenia Marlene |d 1994- |e VerfasserIn |0 (DE-588)1248335058 |0 (DE-627)1783559357 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of clinical psychiatry |d Memphis, Tenn. : Physicians Postgraduate Press, 1996 |g 84(2023), 5, Artikel-ID 22r14626, Seite ? |h Online-Ressource |w (DE-627)32064832X |w (DE-600)2025649-8 |w (DE-576)095092161 |x 1555-2101 |7 nnas |a Therapeutic reference range for olanzapine in schizophrenia systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy |
| 773 | 1 | 8 | |g volume:84 |g year:2023 |g number:5 |g elocationid:22r14626 |g pages:? |g extent:? |a Therapeutic reference range for olanzapine in schizophrenia systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy |
| 856 | 4 | 0 | |u https://doi.org/10.4088/JCP.22r14626 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240913 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1248335058 |a Hart, Xenia Marlene |m 1248335058:Hart, Xenia Marlene |d 60000 |e 60000PH1248335058 |k 0/60000/ |p 14 |y j | ||
| 998 | |g 1078251037 |a Gründer, Gerhard |m 1078251037:Gründer, Gerhard |d 60000 |e 60000PG1078251037 |k 0/60000/ |p 13 | ||
| 998 | |g 1278513981 |a Lense, Xenija M. |m 1278513981:Lense, Xenija M. |d 60000 |e 60000PL1278513981 |k 0/60000/ |p 8 | ||
| 998 | |g 170531007 |a Bergemann, Niels |m 170531007:Bergemann, Niels |d 50000 |e 50000PB170531007 |k 0/50000/ |p 3 | ||
| 998 | |g 1325960853 |a Wesner, Katja |m 1325960853:Wesner, Katja |d 60000 |e 60000PW1325960853 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1902532171 |e 4579433947 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Katja","display":"Wesner, Katja","family":"Wesner"},{"family":"Hiemke","display":"Hiemke, Christoph","role":"aut","given":"Christoph"},{"family":"Bergemann","role":"aut","given":"Niels","display":"Bergemann, Niels"},{"display":"Egberts, Karin M.","given":"Karin M.","role":"aut","family":"Egberts"},{"display":"Fekete, Stefanie","given":"Stefanie","role":"aut","family":"Fekete"},{"display":"Gerlach, Manfred","given":"Manfred","role":"aut","family":"Gerlach"},{"display":"Havemann-Reinecke, Ursula","role":"aut","given":"Ursula","family":"Havemann-Reinecke"},{"family":"Lense","role":"aut","given":"Xenija M.","display":"Lense, Xenija M."},{"family":"Riemer","given":"Thomas G.","role":"aut","display":"Riemer, Thomas G."},{"family":"Schoretsanitis","role":"aut","given":"Georgios","display":"Schoretsanitis, Georgios"},{"display":"Uhr, Manfred","role":"aut","given":"Manfred","family":"Uhr"},{"family":"Zernig","role":"aut","given":"Gerald","display":"Zernig, Gerald"},{"family":"Gründer","display":"Gründer, Gerhard","given":"Gerhard","role":"aut"},{"family":"Hart","display":"Hart, Xenia Marlene","given":"Xenia Marlene","role":"aut"}],"name":{"displayForm":["Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin M. Egberts, Stefanie Fekete, Manfred Gerlach, Ursula Havemann-Reinecke, Xenija M. Lense, Thomas G. Riemer, Georgios Schoretsanitis, Manfred Uhr, Gerald Zernig, Gerhard Gründer, Xenia M. Hart"]},"relHost":[{"origin":[{"publisherPlace":"Memphis, Tenn.","publisher":"Physicians Postgraduate Press","dateIssuedDisp":"1996-","dateIssuedKey":"1996"}],"recId":"32064832X","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"JCP"}],"id":{"zdb":["2025649-8"],"issn":["1555-2101"],"eki":["32064832X"]},"disp":"Therapeutic reference range for olanzapine in schizophrenia systematic review on blood concentrations, clinical effects, and dopamine receptor occupancyThe journal of clinical psychiatry","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 09.01.25"],"title":[{"title":"The journal of clinical psychiatry","subtitle":"JCP","title_sort":"journal of clinical psychiatry"}],"part":{"volume":"84","year":"2023","text":"84(2023), 5, Artikel-ID 22r14626, Seite ?","issue":"5","extent":"?","pages":"?"},"language":["eng"],"pubHistory":["Nachgewiesen 57.1996,10 -"]}],"note":["Gesehen am 13.09.2024"],"physDesc":[{"extent":"? S."}],"id":{"eki":["1902532171"],"doi":["10.4088/JCP.22r14626"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1902532171","origin":[{"dateIssuedDisp":"July 19, 2023","dateIssuedKey":"2023"}],"language":["eng"],"title":[{"title_sort":"Therapeutic reference range for olanzapine in schizophrenia","title":"Therapeutic reference range for olanzapine in schizophrenia","subtitle":"systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy"}]} | ||
| SRT | |a WESNERKATJTHERAPEUTI1920 | ||